Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg)

Inclusion Criteria: * Subjects aged between 18 and 45 years (both inclusive). * Subjects' weight within normal range according to normal values for Body Mass Index (between 18.50 and 30.00 kg/m2) (both inclusive) with minimum of 45 kg weight. * Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable range. * Subject with Creatinine Clearance ≥80 ml/min. * Subjects having clinically acceptable 12-lead electrocardiogram (ECG). * Subjects having clinically acceptable chest X-Ray (PA view), if taken. * Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine). * Subjects having negative urine alcohol test / breath alcohol test. * Non-smokers. * Subjects willing to adhere to the protocol requirements and to provide written informed consent. * For male Subjects: Subjects willing to follow approved birth control methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Subjects willing to refrain from donating sperm during the study period \- For Female Subjects: Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral …